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Abstract The potent anti-hypertensive peptide, RPLKPW, has
been designed based on the structure of ovokinin(2^7). The
sequence encoding this peptide was introduced into three
homologous sites in the gene for soybean L-conglycinin KP
subunit. The native KP subunit as well as the modified,
RPLKPW-containing KP subunit were expressed in Escherichia
coli, recovered from the soluble fraction and then purified by
ion-exchange chromatography. The RPLKPW peptide was
released from recombinant RPLKPW-containing KP subunit
after in vitro digestion by trypsin and chymotrypsin. Moreover,
the undigested RPLKPW-containing KP subunit given orally at
a dose of 10 mg/kg exerted an anti-hypertensive effect in
spontaneously hypertensive rats, unlike the native KP subunit.
These results provide evidence for the first time that a
physiologically active peptide introduced into a food protein by
site-directed mutagenesis could practically function in vivo even
at a low dose. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Hypertension is one of the most common lifestyle-related
diseases. These diseases being closely associated with diet, it is
conceivable that food is conducive to preventing and amelio-
rating such diseases as an adjunct to drug therapy. Therefore,
we tried to develop a novel food protein with anti-hyperten-
sive activity for the dietetics of hypertension.
Previously, we isolated an anti-hypertensive hexapeptide,
ovokinin(2^7) (RADHPF), from a chymotryptic digest of
ovalbumin [1]. Ovokinin(2^7) induces nitric oxide meditated
vasorelaxation. At an oral dose of 10 mg/kg, ovokinin(2^7)
signi¢cantly lowered the systolic blood pressure in spontane-
ously hypertensive rats (SHRs) but failed in normotensive
Wistar^Kyoto rats (WKYs). These results indicate that ovo-
kinin(2^7) possesses an intriguing property to have little e¡ect
on normal blood pressure. However, at least 600 mg/kg of
ovalbumin is required to exert its anti-hypertensive activity
when given orally to SHRs assuming that the peptide is
cleaved from the protein thoroughly.
To obviate such an inconvenience, our e¡orts were centered
on potentiating the anti-hypertensive activity of ovokinin(2^7)
by replacing the amino acid residues in the peptide [2]. Among
various ovokinin(2^7) analogues so far designed, RPLKPW
showed the highest activity, thereby signi¢cantly lowering the
systolic blood pressure of SHRs after oral administration at a
dose of 0.1 mg/kg, a comparable dose to those of synthetic
anti-hypertensive drugs (Yamada et al., Peptides, submitted).
Moreover, the blood pressure in WKYs was not a¡ected by
RPLKPW even at a dose of 1 mg/kg, indicating that this
peptide possesses an ideal, potent anti-hypertensive activity.
In order to utilize the potent anti-hypertensive peptide or
RPLKPW as a food for the dietetics of hypertension, attempts
were made to incorporate the peptide into food protein by
genetic engineering. RPLKPW contains four di¡erent residues
from the original parental peptide ovokinin(2^7). This re-
quired our extensive search for other candidate food proteins
except for ovalbumin as the target. Three RPLKPW-like se-
quences were found in the extension region of soybean L-con-
glycinin KP subunit (Fig. 1). L-Conglycinin, one of the major
soybean storage proteins [3,4], is composed of three subunits,
K, KP and L (543, 559, 416 residues, respectively) [5]. These
homologous sequences were referred to as RPQHPE,
RPRQPH and RPHQPH, corresponding to residues 16^21,
46^51 and 86^91 of the L-conglycinin KP subunit, respectively.
In this report, these three RPLKPW-like sequences in L-con-
glycinin KP subunit were changed to RPLKPW by site-di-
rected mutagenesis of the cDNA encoding the KP subunit.
The modi¢ed protein was produced using an Escherichia coli
expression system to evaluate the anti-hypertensive activity in
SHR.
2. Materials and methods
2.1. Bacterial strain, medium and plasmid
E. coli HMS174(DE3) (Novagen) was used as the host. Luria^Ber-
tani (LB) medium (pH 7.0) consisted of 1% bactotryptone, 0.5% yeast
extract and 1% NaCl. The expression plasmid used here was pECKP
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[5], in which the cDNA encoding the L-conglycinin KP subunit was
subcloned into the expression vector pET21d(+) (Novagen) between
the NcoI and BamHI sites.
2.2. Animals
Male SHRs (16^22 weeks old) were purchased from Shimizu Lab-
oratory Supplies, Kyoto, Japan. Rats were fed with SP chow (Funa-
bashi Farm) and water ad libitum, and housed in a temperature-con-
trolled room with a 12-h light/dark cycle. This study was performed in
accordance with the guidelines for the care and use of laboratory
animals of Kyoto University.
2.3. Site-directed mutagenesis
The expression plasmid pECKP was used as the template for site-
directed mutagenesis. To change three RPLKPW-like sequences in
L-conglycinin KP subunit, or RPQHPE, RPRQPH and RPHQPH,
to RPLKPW, and change the amino acid residues next to the
N-terminus of each of these three sequences to arginine or trypto-
phan, two stages of site-directed mutagenesis with synthetic oligonu-
cleotide primers were performed on the respective regions in pECKP
encoding RPLKPW-like sequences using a QuikChange1 Site-Di-
rected Mutagenesis kit (Stratagene). The primers used were as fol-
lows: (the base sequences for the mutation are underlined) for
RPQHPE, 5P-CCA CGA CCA CGA CCA TTG AAG CCG TGG
AGG GAA CGT CAG CAA CAC-3P and 5P-GTG TTG CTG ACG
TTC CCT CCA CGG CTT CAA TGG TCG TGG TCG TGG-3P
(¢rst stage) and 5P-GAA GGT CAA ATT CCA CGA CGA CGA
CCA TTG AAG CCG-3P and 5P-CGG GTG GAA TGG TCG TCG
TCG TGG AAT TTG ACC TTC-3P (second stage), for RPRQPH, 5P-
CCA TTC CCA CGC CCA CTC AAA CCT TGG CAA GAG GAA
GAG CAC GAG-3P and 5P-CTC GTG CTC TTC CTC TTG CCA
AGG TTT GAG TGG GCG TGG GAA TGG-3P (¢rst stage) and 5P-
CGT CCA TTC CCA TTC TGG CGC CCA CTC AAA CCT TGG
C-3P and 5P-G CCA AGG TTT GAG TGG GCG CCA GAA TGG
GAA TGG ACG-3P (second stage) and for RPHQPH, 5P-GAA CAC
CCA CGC CCA CTC AAA CCT TGG CAA AAG GAA GAG
GAA AAG-3P and 5P-CTT TTC CTC TTC CTT TTG CCA AGG
TTT GAG TGG GCG TGG GTG TTC-3P (¢rst stage) and 5P-GAA
CGT GAA CAC CGA CGC CCA CTC AAA CCT TGG CAA AAG
GAA GAG GAA AAG C-3P and 5P-G CTT TTC CTC TTC CTT
TTG CCA AGG TTT GAG TGG GCG TCG GTG TTC ACG
TTC-3P (second stage). The mutated pECKP was transformed into
E. coli XL1-Blue (Stratagene), and the transformants were cultured
in 3 ml of LB medium containing 50 Wg/ml ampicillin at 37‡C over-
night. After harvesting the cells by centrifugation, the ampli¢ed plas-
mids were extracted. The mutated DNA sequences were con¢rmed by
the dideoxy chain-termination method of Sanger et al. [6], using a
DNA sequencer (Applied Biosystems, Model 310) and an ABI dye
terminator cycle sequencing kit with AmpliTaq polymerase FS (Perkin
Elmer, Applied Biosystems).
2.4. Expression and detection of recombinant native and
RPLKPW-containing KP subunits in E. coli
Flasks of 700 ml of LB medium containing 50 Wg/ml ampicillin were
inoculated with 7 ml of full-grown cultures of HMS174(DE3) harbor-
ing the expression plasmid pECKP or mutated pECKP encoding the
RPLKPW-containing KP subunit and cultured at 37‡C using an orbi-
tal incubator at 200 r.p.m. (Sanyo, Model MIR-220R). At A600 = 0.6^
1.0, isopropyl-1-thio-L-D-galactopyranoside was added to a ¢nal con-
centration of 1 mM to induce expression of the native and RPLKPW-
containing KP subunits. Following induction, culture was continued at
150 r.p.m. for about 42 h at 20‡C. The induced cells were harvested by
centrifugation at 6000Ug for 10 min and stored at 380‡C. Aliquots
of the cells were boiled in sodium dodecyl sulfate (SDS) sample bu¡er
(62.5 mM Tris base, 2% SDS, 10% glycerol and 0.2 M 2-mercapto-
ethanol), and analyzed by SDS^polyacrylamide gel electrophoresis
(SDS^PAGE) using 11% (m/v) acrylamide [7].
2.5. Puri¢cation of recombinant native and RPLKPW-containing KP
subunits from E. coli
All procedures were carried out at 4‡C.
2.5.1. Extraction of the expressed protein from E. coli cells. The
frozen cells were resuspended in bu¡er A (35 mM sodium phosphate,
pH 7.6, 0.2 M NaCl, 10 mM 2-mercaptoethanol, 1 mM EDTA,
0.1 mM (p-amidinophenyl)-methylsulfonyl £uoride (APMSF), 3 Wg/
ml leupeptin and 0.02% NaN3) in a volume of 7 ml per gram of cells
(wet weight), and disrupted by sonication on ice. Insoluble materials
were separated from the soluble fraction by centrifugation at
20 000Ug for 30 min.
2.5.2. Fractionation with ammonium sulfate. The soluble crude ex-
tract was adjusted to 40% (for the native KP subunit) or 20% (for the
RPLKPW-containing KP subunit) saturation with solid ammonium
sulfate and stirred for more than 30 min. After centrifugation at
20 000Ug for 30 min, the supernatant was adjusted to 65% (for the
native KP subunit) or 50% (for the RPLKPW-containing KP subunit)
saturation and stirred overnight. The precipitated protein was col-
lected by centrifugation at 20 000Ug for 30 min, and resuspended in
bu¡er B (35 mM sodium phosphate, pH 7.6, 0.2 M NaCl, 10 mM 2-
mercaptoethanol, 1 mM EDTA, 0.1 mM APMSF, 3 Wg/ml leupeptin
and 0.02% NaN3) in a small volume (up to 10 ml). The suspension
was dialyzed overnight against 3U1 l of bu¡er C (35 mM sodium
phosphate, pH 7.6, 0.1 M NaCl, 10 mM 2-mercaptoethanol, 1 mM
EDTA, 0.1 mM APMSF, 3 Wg/ml leupeptin and 0.02% NaN3).
2.5.3. Q Sepharose column chromatography. The dialysate was
clari¢ed by centrifugation at 20 000Ug for 30 min, and the resulting
protein solution (up to 450 mg protein) was fractionated by anion-
exchange high performance liquid chromatography (HPLC) on a Hi-
Load 26/10 Q Sepharose high performance column (Amersham Phar-
macia Biotech) equilibrated with bu¡er C. The column was initially
washed with bu¡er C until the A280 of the eluate dropped to a stable
baseline, and the elution was performed with a linear gradient of 0.1^
0.6 M NaCl over a period of 250 min. The £ow rate was 4 ml/min and
the fraction size was 6 ml. Fractions containing the recombinant na-
tive and RPLKPW-containing KP subunits were identi¢ed by SDS^
PAGE and pooled. The pooled material was adjusted to 80% satura-
tion with solid ammonium sulfate and stirred overnight. After centri-
fugation at 20 000Ug for 30 min, the precipitated native and modi¢ed
KP subunits were dissolved in distilled water containing 0.1 M NaCl,
pH 7.5, in a volume of V10 ml and dialyzed against 3U2 l of the
same solution for 48 h and an additional 2U3 l of distilled water
overnight. The resulting suspension was freeze-dried and stored at
320‡C. The puri¢ed native and RPLKPW-containing KP subunits
thus obtained were used for further analysis.
2.6. Protein measurement
Proteins in the samples were determined according to the method of
Bradford [8] using bovine serum albumin as a standard.
2.7. Amino acid sequence analysis
The N-terminal sequence of recombinant RPLKPW-containing KP
subunit was determined using a Procise 492 Protein Sequencer (Ap-
plied Biosystems), whereas the C-terminal sequence was determined
using a Procise 494-C Protein Sequencer (Applied Biosystems).
2.8. In vitro digestion of recombinant RPLKPW-containing KP subunit
Recombinant RPLKPW-containing KP subunit (1 mg/ml) was ad-
justed to pH 8.0 and digested with trypsin and chymotrypsin (E/S =
1/400 (w/w)) for 3 h at 37‡C. The reaction was stopped by adding
tri£uoroacetic acid (TFA) to a ¢nal concentration of 0.1%, and then
the reaction mixture was centrifuged.
2.9. Puri¢cation and detection of RPLKPW from the digestion of
recombinant RPLKPW-containing KP subunit
The digest was fractionated by reversed-phase HPLC on an octa-
decyl silica (ODS) column (Cosmosil 5C18-AR-II, 4.6U150 mm, Na-
calai Tesque). The column was eluted with a linear gradient of aceto-
nitrile (1%/min), containing 0.1% TFA at a £ow rate of 1 ml/min.
Elution was monitored at 280 nm. The expected fraction containing
RPLKPW was collected according to the elution position of the syn-
thetic peptide. The fraction was concentrated in a centrifugal concen-
trator, and applied to a liquid chromatograph mass spectrometry
(Mariner, PerSeptive Biosystems) or a 492 protein sequencer (Applied
Biosystems).
2.10. Measurement of the blood pressure after oral administration of
recombinant native and RPLKPW-containing KP subunits to
SHRs
The recombinant native and RPLKPW-containing KP subunits were
emulsi¢ed with 30% egg yolk in saline and administered orally to
SHRs using a metal zonde in a volume of 0.5 ml [9]. The systolic
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blood pressure was measured by the indirect tail cu¡ method using an
MK-2000 (Muromachi Kikai). Following oral administration, the
blood pressure was measured every 2 h.
2.11. Data analyses
Results of blood pressure measurements are expressed as means
þ S.E.M. Statistical evaluation was performed by analysis of variance
(ANOVA). Values of P6 0.05 were considered statistically signi¢cant.
3. Results
3.1. Introduction of RPLKPW sequences into L-conglycinin KP
subunit
Three RPLKPW-like sequences including RPQHPE,
RPRQPH and RPHQPH, corresponding to residues 16^21,
46^51 and 86^91 of L-conglycinin KP subunit, respectively,
were changed to RPLKPW by site-directed mutagenesis of
the cDNA encoding the KP subunit in the expression plasmid
pECK. All these sequences are preceded by Pro residues. To
facilitate the release of RPLKPW from the modi¢ed KP sub-
unit in the intestine after ingestion of the protein, the Pro
residues should also be changed to arginine or tryptophan
(Fig. 1). This modi¢cation allowed the RPLKPW sequences
to be released by trypsin and chymotrypsin. As a result, four
residues were replaced in each site.
3.2. Expression and detection of recombinant native and
RPLKPW-containing KP subunits in E. coli
Expression of recombinant native and RPLKPW-contain-
ing KP subunits in E. coli cells harboring individual expression
plasmids was assessed by SDS^PAGE. Densitometric scan-
ning of the gels indicated that both the native and
RPLKPW-containing KP subunits accumulated in E. coli at
a level of around 15% of the total bacterial proteins (Fig. 2,
lanes 2 and 6). The mobility of the RPLKPW-containing KP
subunit on SDS^PAGE was slightly faster than that of the
native molecule. Immunoblotting analysis revealed that both
Fig. 1. Three RPLKPW-like sequences in a soybean L-conglycinin KP subunit (A) and the design of site-directed mutagenesis (B). Bold letters
in (A) correspond to the extension region. Putative trypsin or chymotrypsin cleavage sites are indicated by the dotted line in (B).
Fig. 2. SDS^PAGE analysis of the native and the RPLKPW-containing L-conglycinin KP subunit. Recombinant native (lanes 2^5) and modi¢ed
(lanes 6^9) were expressed in E. coli HMS174(DE3). Lane 1, non-transformed E. coli proteins; lanes 2 and 6, total cell proteins after expres-
sion; lanes 3 and 7, soluble cell proteins; lanes 4 and 8, insoluble cell proteins obtained by sonicating the cells ; lanes 5 and 9, puri¢ed native
and modi¢ed KP subunits by Q Sepharose column.
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the native and the RPLKPW-containing KP subunit were rec-
ognized by anti-recombinant KP subunit antiserum (data not
shown). Both the native and RPLKPW-containing KP sub-
units were recovered mostly in the soluble fractions (Fig. 2,
lanes 3 and 7).
Recombinant native and RPLKPW-containing KP subunits
in the soluble fractions were puri¢ed using ammonium sulfate
as the ¢rst step. The native KP subunit was precipitated in the
40^65% ammonium sulfate fraction, whereas the RPLKPW-
containing KP was precipitated in the 20^50% fraction. After
dialysis, the pure KP subunits were obtained by anion-ex-
change chromatography using a Q Sepharose column (Fig.
2, lanes 5 and 9, Fig. 3). As a result, 13.9 mg of the native
KP subunit and 14.6 mg of the modi¢ed protein were each
obtained from 2.8 l of culture.
To verify that the obtained RPLKPW-containing KP sub-
unit still remained in the complete form, the N- and C-termi-
nal amino acid sequences of the protein were analyzed. Both
the sequences determined here (seven residues of the N-termi-
nus and three residues of the C-terminus) coincided with those
of the native KP subunit reported previously [5]. About three
quarters of both the native and the modi¢ed protein had an
additional N-terminal methionine residue.
3.3. In vitro digestion of recombinant RPLKPW-containing KP
subunit and detection of RPLKPW
To determine whether RPLKPW could be released from
recombinant RPLKPW-containing KP subunit as expected,
the modi¢ed KP was digested with trypsin and chymotrypsin
in vitro. After fractionation of the digest by HPLC using an
ODS column, the fraction with the same retention time as that
of synthetic RPLKPW was analyzed by liquid chromatograph
mass spectrometry, and a peak with the same molecular mass
as RPLKPW was detected. For further veri¢cation, the frac-
tion was applied to a protein sequencer. The sequence deter-
mined here coincided completely with RPLKPW. The overall
yield of the ¢nally puri¢ed RPLKPW was V1%.
3.4. Anti-hypertensive activity of recombinant
RPLKPW-containing KP subunit
The results of in vitro digestion of recombinant RPLKPW-
containing KP subunit suggested that RPLKPW could be re-
leased by intestinal trypsin and chymotrypsin after ingestion
of the non-digested protein, thereby allowing prompt investi-
gation of the anti-hypertensive e¡ects after its oral adminis-
tration to SHR.
As shown in Fig. 4, orally administered recombinant
RPLKPW-containing KP subunit at a dose of 10 mg/kg sig-
ni¢cantly lowered the systolic blood pressure of SHRs 4 h
after administration. The lowered blood pressure returned to
the basal level 6 h post-administration. At a dose of 5 mg/kg,
the RPLKPW-containing KP subunit failed to show the anti-
hypertensive e¡ect, indicating that the minimal e¡ective dose
of the RPLKPW-containing KP subunit is 5^10 mg/kg. In
contrast, however, the native KP subunit at a dose of 20 mg/
kg had no e¡ect on the blood pressure.
4. Discussion
In this study, three sets of RPLKPW, an orally active,
potent anti-hypertensive peptide that has been designed on
structure^activity relationship study of ovokinin(2^7), were
introduced into the homologous sequences of soybean L-con-
glycinin KP subunit by site-directed mutagenesis. After oral
administration to SHRs, recombinant RPLKPW-containing
KP subunit successfully lowered the blood pressure at a dose
of 10 mg/kg. As the minimal e¡ective dose of the RPLKPW
was 0.1 mg/kg when given orally to SHR, at least 30% of the
integrated RPLKPW in the RPLKPW-containing KP subunit
should be released in the gastrointestinal tract of SHRs orally
medicated with this protein. On the other hand, ovalbumin
exerted its anti-hypertensive activity at a dose of as high as
2 g/kg (data not shown), indicating that the RPLKPW-con-
taining KP subunit designed here has a 200-fold potent anti-
hypertensive e¡ect compared to ovalbumin. Coupled with
Fig. 3. Puri¢cation of recombinant KP subunits from the total E.
coli proteins by anion-exchange HPLC on a Q Sepharose column.
(A) The native KP subunit. (B) The RPLKPW-containing KP sub-
unit. Fractions containing the KP subunits are indicated by arrows.
Fig. 4. Anti-hypertensive activity of RPLKPW-containing L-congly-
cinin KP subunit after oral administration in SHRs. The numbers of
experiments are shown in parentheses. Changes in systolic blood
pressure from zero time are expressed as means þ S.E.M. Statistical
evaluation was performed by ANOVA. *Signi¢cantly di¡erent from
the native KP group (*P6 0.05).
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these facts, the RPLKPW-containing KP subunit proved to
have a potent anti-hypertensive e¡ect as a designed food pro-
tein.
The maximum decrease in the blood pressure was noted 4 h
after administration of the recombinant RPLKPW-containing
KP subunit. The time-course pattern of the onset was consis-
tent with those after administration of the free RPLKPW
peptide, indicating that the peptide was liberated from the
protein rapidly after ingestion. All the three RPLKPW-con-
taining sequences might be vulnerable to easy cleavage due to
their speci¢c location on the extension region of the KP sub-
unit, which is hydrophilic by itself and projected on the sur-
face of the molecule [5].
Although the molecular mass of recombinant RPLKPW-
containing KP subunit was not signi¢cantly di¡erent from
that of the native protein, the RPLKPW-containing KP sub-
unit showed a slightly faster electrophoretic mobility relative
to the native protein on SDS^PAGE. However, analysis of
both N- and C-terminal amino acid sequences suggested
that no processing had occurred on the RPLKPW-containing
KP subunit. The mobility shift could be explained by some
conformational change of the RPLKPW-containing KP sub-
unit. The RPLKPW-containing KP subunit was, however, re-
covered in the soluble fraction in E. coli, suggesting that the
protein was folded normally. Moreover, the extension region
of the KP subunit was suggested to have a minor role in proper
folding [5]. This indicates that no signi¢cant changes occurred
in the overall conformation of the RPLKPW-containing KP
subunit, although further investigations such as circular di-
chroism measurement are required.
It is noteworthy that the intact RPLKPW-containing KP
subunit exhibited anti-hypertensive e¡ects, thereby being in-
dicative of the RPLKPW-containing KP subunit as an anti-
hypertensive food protein. It remains to be investigated
whether recombinant RPLKPW-containing KP subunit could
be produced and accumulated properly in plant tissue. Glyci-
nin, another major soybean storage protein, was shown to
have the correct conformation after expressed in E. coli [10]
and accumulate stably in rice [11], potato [12] and tobacco
seed [13] even after modi¢cation in its variable region. Con-
sequently, we regard rice especially as another candidate to
produce the RPLKPW-containing KP subunit besides soybean.
Most genetically modi¢ed (GM) crops marketed to date have
been developed to bring great pro¢t to farmers by introduc-
tion of genes conferring properties such as insect resistance
and herbicide tolerance. As the natural consequence, with the
expectation that a second generation of GM crops bringing
about bene¢t to the consumers would be attained [14], various
crops with bene¢cial health e¡ects are now being explored
[15^18]. Although further investigations with regard to the
safety evaluation (e.g. allergenicity, chronic toxicity etc.) re-
main to be performed, incorporation of the RPLKPW-con-
taining KP subunit into crops could assume a greater role in
establishing novel GM crops for dietetics of hypertension in
the near future.
This study showed for the ¢rst time that physiologically
active peptides introduced in a food protein by site-directed
mutagenesis could practically function in vivo. These obser-
vations will open new avenues of study on the physiologically
active peptides derived from food proteins, leading to the
second generation of GM crops with bene¢cial health e¡ects.
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